The legal action alleges that Immutep violated the Securities Exchange Act of 1934 by concealing critical failures in the TACTI-004 trial of eftilagimod alfa. While the company filed a Form-K on January 30, 2026, asserting strong progress, the complaint claims executives were already aware that the trial would miss its primary efficacy endpoints. Investors seeking to participate in the potential recovery must contact the firm by July 6, 2026.

Brian Schall of The Schall Law Firm is overseeing the case from his Los Angeles office. Shareholders who suffered losses during the specified period may discuss their legal standing at no cost. Until the court formally certifies the class, investors remain absent members without direct legal representation unless they proactively join the proceedings.